{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T14:04:10Z","timestamp":1751033050372},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,24]]},"DOI":"10.7759\/cureus.65261","type":"journal-article","created":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T11:49:10Z","timestamp":1721821750000},"source":"Crossref","is-referenced-by-count":1,"title":["Therapeutic Potential of Intravenous Ketamine in Early-Onset Dementia: A Case Report"],"prefix":"10.7759","author":[{"given":"Mariam","family":"Tadros","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dianella","family":"Rente Lavastida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashraf","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.4782","article-title":"Diagnosis and management of dementia: a review","volume":"322","author":"Arvanitakis Z","year":"2019","unstructured":"Arvanitakis Z, Shah RC, Bennett DA. Diagnosis and management of dementia: a review. JAMA. 2019, 322:1589-99. 10.1001\/jama.2019.4782","journal-title":"JAMA"},{"key":"ref2","unstructured":"National Institute on Aging. How biomarkers help diagnose dementia. (2022). Accessed. June 28, 2024: https:\/\/www.nia.nih.gov\/health\/alzheimers-symptoms-and-diagnosis\/how-biomarkers-help-diagnose-dementia."},{"key":"ref3","unstructured":"CNS Vital Signs. Clinical practice. (2024). Accessed. May 13, 2024: https:\/\/www.cnsvs.com\/ClinicalPractice.html."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113168","article-title":"Overview of therapeutic targets in management of dementia","volume":"152","author":"Malik R","year":"2022","unstructured":"Malik R, Kalra S, Bhatia S, et al.. Overview of therapeutic targets in management of dementia. Biomed Pharmacother. 2022, 152:113168. 10.1016\/j.biopha.2022.113168","journal-title":"Biomed Pharmacother"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2005.09.007","article-title":"Mechanism of action of memantine","volume":"6","author":"Johnson JW","year":"2006","unstructured":"Johnson JW, Kotermanski SE. Mechanism of action of memantine. Curr Opin Pharmacol. 2006, 6:61-7. 10.1016\/j.coph.2005.09.007","journal-title":"Curr Opin Pharmacol"},{"key":"ref6","article-title":"The anti-inflammatory effects of ketamine: state of the art","volume":"62","author":"Loix S","year":"2011","unstructured":"Loix S, De Kock M, Henin P. The anti-inflammatory effects of ketamine: state of the art. Acta Anaesthesiol Belg. 2011, 62:47-58.","journal-title":"Acta Anaesthesiol Belg"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1213\/ANE.0000000000001787","article-title":"Intravenous ketamine infusions for neuropathic pain management: a promising therapy in need of optimization","volume":"124","author":"Maher DP","year":"2017","unstructured":"Maher DP, Chen L, Mao J. Intravenous ketamine infusions for neuropathic pain management: a promising therapy in need of optimization. Anesth Analg. 2017, 124:661-74. 10.1213\/ANE.0000000000001787","journal-title":"Anesth Analg"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/neurolint14020025","article-title":"The possible application of ketamine in the treatment of depression in Alzheimer's disease","volume":"14","author":"Mohammad Shehata I","year":"2022","unstructured":"Mohammad Shehata I, Masood W, Nemr N, et al.. The possible application of ketamine in the treatment of depression in Alzheimer's disease. Neurol Int. 2022, 14:310-21. 10.3390\/neurolint14020025","journal-title":"Neurol Int"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.1173-17.2017","article-title":"Memantine and ketamine differentially alter NMDA receptor desensitization","volume":"37","author":"Glasgow NG","year":"2017","unstructured":"Glasgow NG, Povysheva NV, Azofeifa AM, Johnson JW. Memantine and ketamine differentially alter NMDA receptor desensitization. J Neurosci. 2017, 37:9686-704. 10.1523\/JNEUROSCI.1173-17.2017","journal-title":"J Neurosci"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2019.11.028","article-title":"Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression","volume":"263","author":"Acevedo-Diaz EE","year":"2020","unstructured":"Acevedo-Diaz EE, Cavanaugh GW, Greenstein D, Kraus C, Kadriu B, Zarate CA, Park LT. Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression. J Affect Disord. 2020, 263:568-75. 10.1016\/j.jad.2019.11.028","journal-title":"J Affect Disord"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2019.00186","article-title":"Ketamine: a neglected therapy for Alzheimer disease","volume":"11","author":"Smalheiser NR","year":"2019","unstructured":"Smalheiser NR. Ketamine: a neglected therapy for Alzheimer disease. Front Aging Neurosci. 2019, 11:186. 10.3389\/fnagi.2019.00186","journal-title":"Front Aging Neurosci"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001191.pub2","article-title":"Rivastigmine for Alzheimer's disease","volume":"2","author":"Birks J","year":"2009","unstructured":"Birks J, Grimley Evans J, Iakovidou V, Tsolaki M, Holt FE. Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev. 2009, 2:CD001191. 10.1002\/14651858.CD001191.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref13","article-title":"Brain imaging in differential diagnosis of dementia","volume":"2019","author":"Ayers M","year":"2019","unstructured":"Ayers M, Svaldi D, Apostolova L. Brain imaging in differential diagnosis of dementia. Pract Neurol. 2019, 2019:1-7.","journal-title":"Pract Neurol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2018.1471136","article-title":"Pharmacotherapy for the treatment of depression in patients with Alzheimer's disease: a treatment-resistant depressive disorder","volume":"19","author":"Lozupone M","year":"2018","unstructured":"Lozupone M, La Montagna M, D'Urso F, et al.. Pharmacotherapy for the treatment of depression in patients with Alzheimer's disease: a treatment-resistant depressive disorder. Expert Opin Pharmacother. 2018, 19:823-42. 10.1080\/14656566.2018.1471136","journal-title":"Expert Opin Pharmacother"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jagp.2024.01.117","article-title":"Is there evidence for using ketamine among individuals with dementia?","volume":"32","author":"Kapoor A","year":"2024","unstructured":"Kapoor A, Estevez TP, Yamagata N, Chan C, Doumlele K, Tampi RR. Is there evidence for using ketamine among individuals with dementia?. Am J Geriatr Psychiatry. 2024, 32:45-6. 10.1016\/j.jagp.2024.01.117","journal-title":"Am J Geriatr Psychiatry"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-021-01327-5","article-title":"Acute cognitive effects of single-dose intravenous ketamine in major depressive and posttraumatic stress disorder","volume":"11","author":"Davis MT","year":"2021","unstructured":"Davis MT, DellaGiogia N, Maruff P, Pietrzak RH, Esterlis I. Acute cognitive effects of single-dose intravenous ketamine in major depressive and posttraumatic stress disorder. Transl Psychiatry. 2021, 11:205. 10.1038\/s41398-021-01327-5","journal-title":"Transl Psychiatry"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.29158\/JAAPL.230040-23","article-title":"Regulating ketamine use in psychiatry","volume":"51","author":"Harding L","year":"2023","unstructured":"Harding L. Regulating ketamine use in psychiatry. J Am Acad Psychiatry Law. 2023, 51:320-5. 10.29158\/JAAPL.230040-23","journal-title":"J Am Acad Psychiatry Law"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2023.1145318","article-title":"Tau protein plays a role in the mechanism of cognitive disorders induced by anesthetic drugs","volume":"17","author":"Chen Z","year":"2023","unstructured":"Chen Z, Wang S, Meng Z, et al.. Tau protein plays a role in the mechanism of cognitive disorders induced by anesthetic drugs. Front Neurosci. 2023, 17:1145318. 10.3389\/fnins.2023.1145318","journal-title":"Front Neurosci"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/258240-therapeutic-potential-of-intravenous-ketamine-in-early-onset-dementia-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T11:49:15Z","timestamp":1721821755000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/258240-therapeutic-potential-of-intravenous-ketamine-in-early-onset-dementia-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,24]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.65261","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,24]]}}}